The Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, Maryland.
Department of Pathology, Central Hospital affiliated with Shenyang Medical College, Shenyang, Liaoning Province, China.
Clin Cancer Res. 2017 Dec 1;23(23):7333-7339. doi: 10.1158/1078-0432.CCR-17-0950. Epub 2017 Sep 19.
Hepatocellular carcinoma (HCC) often arises in the setting of chronic liver inflammation and may be responsive to novel immunotherapies. To characterize the immune microenvironment in HCC, IHC staining was performed for CD8-positive T lymphocytes, PD-1-positive, and LAG-3-positive lymphocytes, CD163-positive macrophages, and PD-L1 expression in tumor and liver background from 29 cases of resected HCC. Expression of CD8 was reduced in tumor, and expression of CD163 was reduced at the tumor interface. Positive clusters of PD-L1 expression were identified in 24 of 29 cases (83%), and positive expression of LAG-3 on tumor-infiltrating lymphocytes was identified in 19 of 29 cases (65%). The expression of both PD-L1 and LAG-3 was increased in tumor relative to liver background. No association between viral status or other clinicopathologic features and expression of any of the IHC markers investigated was noted. LAG-3 and PD-L1, two inhibitory molecules implicated in CD8 T-cell tolerance, are increased in most HCC tumors, providing a basis for investigating combinatorial checkpoint blockade with a LAG-3 and PD-L1 inhibitor in HCC. .
肝细胞癌 (HCC) 常发生于慢性肝脏炎症的背景下,可能对新型免疫疗法有反应。为了描述 HCC 的免疫微环境,对 29 例切除的 HCC 肿瘤和肝背景中的 CD8 阳性 T 淋巴细胞、PD-1 阳性和 LAG-3 阳性淋巴细胞、CD163 阳性巨噬细胞和 PD-L1 表达进行了免疫组化染色。肿瘤中 CD8 的表达减少,肿瘤界面处 CD163 的表达减少。在 29 例中有 24 例(83%)鉴定出 PD-L1 表达阳性簇,在 29 例中有 19 例(65%)鉴定出肿瘤浸润淋巴细胞上 LAG-3 的阳性表达。与肝背景相比,肿瘤中 PD-L1 和 LAG-3 的表达均增加。未观察到病毒状态或其他临床病理特征与任何研究的免疫组化标志物的表达之间存在关联。LAG-3 和 PD-L1 是两种与 CD8 T 细胞耐受相关的抑制性分子,在大多数 HCC 肿瘤中增加,为在 HCC 中联合检查点阻断 LAG-3 和 PD-L1 抑制剂提供了基础。